Help us: Donate
Follow us on:



ChromaDex Announces $25 Million Private Placement of Common Stock

The company's products have proven popular with biohackers.


ChromaDex has recently announced that it has agreed a securities purchase agreement for the sale of $25 million of its common stock in a private placement. The private placement was led by an international investor, with ChromaDex agreeing to sell 3,846,153 shares of its common stock at a per-share price of $6.50.

ChromaDex is the manufacturer of the popular supplement nicotinamide riboside (NR), a precursor of nicotinamide adenine dinucleotide (NAD+) and a major regulator of energy metabolism. ChromaDex sells its NR via the brand name Tru Niagen.

ChromaDex has proven popular with biohackers

The company has become well known in biohacking and supplement enthusiast circles and has even attracted the attention of actress and fitness guru Brooke Burke, who some readers may know from Dancing with the Stars, which she initially won and then went on to co-host. Interestingly, Brooke Burke is also a self-confessed biohacking geek and is interested in the rising trend of wellness, which includes dietary supplements, fitness, and healthy aging.

Melissa Meyers, Creative Director of the lifestyle blog The Glow Girl, is another popular personality who has been enthusiastic about NR. She is one of a growing number of influencers who embrace aging and give advice on how to age gracefully, or as we like to think of it, how to best cope with the fact we are all slowly falling apart.

Of course, our field has far more ambitious ideas about what to do about aging, but it is good that at least an increasing number of people are getting around to the idea that there are things that they can do to potentially slow aging down. This is not necessarily a bad thing while we wait, as better things are developed that could potentially reverse aging on a cellular level.

It’s likely that we are really not that far away from seeing the first human therapies that target aging; we discuss some of these near-future technologies, drugs, and companies in Looking Forward to a Productive 2021 in Aging Research.

The future of ChromaDex

“With this additional capital, we intend to further our position as the world’s leading NAD+ company with expanded scientific research on nicotinamide riboside (NR) and other NAD+ precursors,” says ChromaDex CEO Rob Fried in his company’s press release. “We will also expand our marketing efforts on our flagship consumer brand, Tru Niagen, the safest and most efficient way to boost NAD+ levels, while continuing to protect our intellectual property against infringers.”

The last part is surely a reference to the legal battle that ChromaDex has been having with rival NR company Elysium. Originally, Elysium was supplied by ChromaDex and used its NR in Basis, one of Elysium’s products; however, the supply arrangement was ended and their relationship unraveled, ultimately descending into legal battles.

In 2018, ChromaDex filed a suit against Elysium for infringement of its NR patent, and this is almost certainly what the last part of its press release statement is referring to. The suit is slated to go to court in September 2021, and we will be following the outcome of that case closely to see if ChromaDex can retain the sole right to manufacture and supply NR.

Legal battles aside, we hope that the future development for NR will include more clinical trials and testing of the supplement, including fair comparative studies alongside other NAD+ precursors.

We would like to ask you a small favor. We are a non-profit foundation, and unlike some other organizations, we have no shareholders and no products to sell you. We are committed to responsible journalism, free from commercial or political influence, that allows you to make informed decisions about your future health.

All our news and educational content is free for everyone to read, but it does mean that we rely on the help of people like you. Every contribution, no matter if it’s big or small, supports independent journalism and sustains our future. You can support us by making a donation or in other ways at no cost to you.

Rejuvenation Roundup May 2023

This year, May brought us a shower of research, interviews, and insights into the present and future of rejuvenation biotechnology....

Dietary Magnesium in Dementia Prevention

Researchers publishing in the European Journal of Nutrition looked into magnesium as a possible candidate for preventing dementia, focusing on...

Glycine and Cysteine Combo Rescues Cognitive Decline in Mice

Scientists publishing in Antioxidants have reported that increasing glutathione levels with GlyNAC, a supplement that combines glycine and cysteine, significantly...

Vitalik Buterin Exclusive Interview: Longevity, AI and More

Vitalik Buterin holding Zuzu, the puppy rescued by people of Zuzalu. Photo: Michelle Lai Don’t try finding Zuzalu on a...

About the author

Steve Hill

Steve serves on the LEAF Board of Directors and is the Editor in Chief, coordinating the daily news articles and social media content of the organization. He is an active journalist in the aging research and biotechnology field and has to date written over 600 articles on the topic, interviewed over 100 of the leading researchers in the field, hosted livestream events focused on aging, as well as attending various medical industry conferences. His work has been featured in H+ magazine, Psychology Today, Singularity Weblog, Standpoint Magazine, Swiss Monthly, Keep me Prime, and New Economy Magazine. Steve is one of three recipients of the 2020 H+ Innovator Award and shares this honour with Mirko Ranieri – Google AR and Dinorah Delfin – Immortalists Magazine. The H+ Innovator Award looks into our community and acknowledges ideas and projects that encourage social change, achieve scientific accomplishments, technological advances, philosophical and intellectual visions, author unique narratives, build fascinating artistic ventures, and develop products that bridge gaps and help us to achieve transhumanist goals. Steve has a background in project management and administration which has helped him to build a united team for effective fundraising and content creation, while his additional knowledge of biology and statistical data analysis allows him to carefully assess and coordinate the scientific groups involved in the project.
  1. barryathome
    February 25, 2021

    Even if ChromaDex wins a judgement against Elysium it will be hard to maintain sole control over NR material. There are numerous manufacturers, mostly in China who are producing material and as with other substances it will be hard to chase down all the players and enforce patent. I think much of the spin around NR ignores or downplays cheaper and non patentable materials like niacin/ niacinamide that are available at a fraction of the cost. I have not seen any thorough comparisons and weak criticisms such as niacin causing flushing and the unproven conclusions about niacinamide causing sirtuin inhibition. There are studies out there showing elevated sirtuin after niacinamide treatment.That being said NR is an interesting material that I take in conjunction with other NAD precursors . I have beenβ€˜bio hacking’ since the 1980s and an early adopter who has made many over enthusiastic mistakes and watched theories/ approaches crumble. Newer papers alluding to NAD promoting SASP and possible roll in some cancers are worth considering… the body is a complicated place.

    • Steve Hill
      February 25, 2021

      I suspect you are right Barry and I broadly agree with your other comments here. I have written quite a bit about NAD+ on here and I take Niacin myself, over 3 years, and I think it has its place.

    • mpease
      February 25, 2021

      Hi Barry. What do you think of the Chinese stuff. I see NR on aliexpress for about $100 a KG!

Write a comment:


Your email address will not be published.

This site uses Akismet to reduce spam. Learn how your comment data is processed.